Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) - An oral, direct factor Xa inhibitor

Thrombosis and Haemostasis

Volumn 97, Issue 3, 2007, Pages 471-477

  Biemond, Bart J ^a   Perzborn, Elisabeth ^b   Friederich, Philip W ^a   Levi, Marcel ^a   Buetehorn, Ulf ^b   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BAYER PHARMA AG   (Germany)

Author keywords

Factor Xa inhibitor; Oral anticoagulant; Prophylaxis; Rivaroxaban; Venous thrombosis

Indexed keywords

ARIXTA; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN; FONDAPARINUX; NADROPARIN; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; JUGULAR VEIN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOGENESIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; JUGULAR VEINS; LIGATION; MORPHOLINES; NADROPARIN; POLYSACCHARIDES; RABBITS; RANDOM ALLOCATION; THIOPHENES; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 33947322997     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-11-0620     Document Type: Article

References (27)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
2. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-625.
3. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
4. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surger: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
5. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
6. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S.
7. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458-2463.
8. Ruivard M, Berger C, Achaibi A, et al. Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. J Gen Intern Med 2003; 18: 903-907.
9. Scott PA, Pancioli AM, Davis LA, et al. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 2002; 33: 2664-2669.
10. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
11. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. J Thromb Haemost 2005; 3: Abstract P1104.
12. Weinz C, Buetchorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs. Xenobiotica 2005; 35: 891-910.
13. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
14. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-128.
15. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-2486.
16. Berry CN, Girard D, Girardot C, et al. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996; 22: 233-241.
17. Millet J, Theveniaux J, Brown NL. The venous antithrombotic profile of naroparcil in the rabbit. Thromb Haemost 1994; 72: 874-879.
18. Saivin S, Caranobe C, Petitou M, et al. Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits. Br J Haematol 1992; 80: 509-513.
19. Biemond BJ, Levi M, Nurmohamed MT, et al. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. Thromb Haemost 1994; 72: 377-380.
20. Biemond BJ, Friederich PW, Levi M, et al. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-160.
21. Friederich PW, Keller TT, Biemond BJ, et al. Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. Thromb Haemost 2000; 84: 858-864.
22. Levi M, Friederich PW, Middleton S, et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999; 5: 107-111.
23. ten Cate H, Lamping RJ, Henny CP et al. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30: 860-864.
24. Weinz C, Schwartz T, Pleiss U, et al. Metabolism and distribution of[14C]BAY 59-7939-an oral, direct factor Xa inhibitor - in rat, dog and human. Drug Metab Rev 2004; 36 (Suppl 1): 98 (Abstract 196).
25. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
26. Leadley RJ, Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001; 1: 151-159.
27. Wong PC, Crain EJ, Watson CA, et al. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 2002; 303: 993-1000.